Latest Observability News

D3 Energy has submitted its Production Right application for part of its South African ER315 permit well ahead of schedule and under budget, marking a key step toward commercialising certified methane and helium reserves.

Prophecy International flags higher churn and softer US sales for its Snare product, prompting a conservative FY2026 outlook and $3.2 million in annual cost savings.

S&P Dow Jones Indices has announced its September 2025 quarterly rebalance, with significant additions and removals across multiple ASX indices set to take effect before market open on September 22.

NT Minerals has completed the sale of its Redbank and Wollogorang copper projects to Golden Horse Minerals for $1 million cash plus equity valued at over $2 million, maintaining an indirect stake through escrowed shares.

Rubix Resources Limited has responded to ASX inquiries about unusual trading activity by disclosing initial drilling observations at its Paperbark Project and preliminary discussions on a potential acquisition, while cancelling a planned capital raising.

ALCORE, ABx Group’s subsidiary, has secured government approval for overseas R&D activities and is pursuing a $5 million grant to accelerate its clean fluorine chemical technology commercialisation.

Greenvale Energy's maiden drilling at the Oasis Uranium Project in Queensland has revealed multiple high-grade uranium zones, confirming mineralisation continuity and significant depth extensions. These promising results underscore the project's growth potential and position Greenvale as a rising uranium explorer.

Verity Resources has successfully raised $3 million through a two-tranche placement to accelerate drilling and resource upgrades at its Monument Gold Project amid strong gold market conditions.

Kinetiko Energy has secured a crucial two-year renewal of its South African exploration rights, advancing its pilot production and development plans amid promising drilling results.

Krakatoa Resources has lodged a strategic application to expand its Mt Clere Project eastward, potentially extending its rare earth footprint by over 9km at Dingo Pass, while completing a key drilling program at Stone Tank.

Amplia Therapeutics has commenced dosing the first patient in its new pancreatic cancer trial combining narmafotinib with FOLFIRINOX chemotherapy, marking a key milestone in its drug development journey.

Jatcorp announces the immediate resignation of CEO Sunny Liang, appointing Executive Director Dr Sean Li as acting CEO during the search for a permanent replacement.